265 related articles for article (PubMed ID: 30548627)
1. Predictive probability of success using surrogate endpoints.
Saint-Hilary G; Barboux V; Pannaux M; Gasparini M; Robert V; Mastrantonio G
Stat Med; 2019 May; 38(10):1753-1774. PubMed ID: 30548627
[TBL] [Abstract][Full Text] [Related]
2. Simulation optimization for Bayesian multi-arm multi-stage clinical trial with binary endpoints.
Yu Z; Ramakrishnan V; Meinzer C
J Biopharm Stat; 2019; 29(2):306-317. PubMed ID: 30763151
[TBL] [Abstract][Full Text] [Related]
3. Decision-making in drug development using a composite definition of success.
Saint-Hilary G; Robert V; Gasparini M
Pharm Stat; 2018 Sep; 17(5):555-569. PubMed ID: 29956453
[TBL] [Abstract][Full Text] [Related]
4. A Bayesian prediction model between a biomarker and the clinical endpoint for dichotomous variables.
Jiang Z; Song Y; Shou Q; Xia J; Wang W
Trials; 2014 Dec; 15():500. PubMed ID: 25528466
[TBL] [Abstract][Full Text] [Related]
5. Bayesian adaptive trial design for a newly validated surrogate endpoint.
Renfro LA; Carlin BP; Sargent DJ
Biometrics; 2012 Mar; 68(1):258-67. PubMed ID: 21838811
[TBL] [Abstract][Full Text] [Related]
6. Assurance in vaccine efficacy clinical trial design based on immunological responses.
Callegaro A; Zahaf T; Tibaldi F
Biom J; 2021 Oct; 63(7):1434-1443. PubMed ID: 34254347
[TBL] [Abstract][Full Text] [Related]
7. Using short-term endpoints to improve interim decision making and trial duration in two-stage phase II trials with nested binary endpoints.
Zocholl D; Kunz CU; Rauch G
Stat Methods Med Res; 2023 Sep; 32(9):1749-1765. PubMed ID: 37489267
[TBL] [Abstract][Full Text] [Related]
8. Uncertainty in the Bayesian meta-analysis of normally distributed surrogate endpoints.
Bujkiewicz S; Thompson JR; Spata E; Abrams KR
Stat Methods Med Res; 2017 Oct; 26(5):2287-2318. PubMed ID: 26271918
[TBL] [Abstract][Full Text] [Related]
9. An optimal Bayesian predictive probability design for phase II clinical trials with simple and complicated endpoints.
Guo B; Liu S
Biom J; 2020 Mar; 62(2):339-349. PubMed ID: 31402481
[TBL] [Abstract][Full Text] [Related]
10. Bayesian model selection techniques as decision support for shaping a statistical analysis plan of a clinical trial: an example from a vertigo phase III study with longitudinal count data as primary endpoint.
Adrion C; Mansmann U
BMC Med Res Methodol; 2012 Sep; 12():137. PubMed ID: 22962944
[TBL] [Abstract][Full Text] [Related]
11. Sample size reestimation and Bayesian predictive probability for single-arm clinical trials with a time-to-event endpoint using Weibull distribution with unknown shape parameter.
Waleed M; He J; Phadnis MA
J Biopharm Stat; 2024 Jul; 34(4):469-487. PubMed ID: 37545144
[TBL] [Abstract][Full Text] [Related]
12. Optimal decision-making in oncology development programs based on probability of success for phase III utilizing phase II/III data on response and overall survival.
Götte H; Xiong J; Kirchner M; Demirtas H; Kieser M
Pharm Stat; 2020 Nov; 19(6):861-881. PubMed ID: 32662598
[TBL] [Abstract][Full Text] [Related]
13. An analytical approach to assess the predictive value of biomarkers in Phase II decision making.
Nikolakopoulos S; van der Wal WM; Roes KC
J Biopharm Stat; 2013; 23(5):1106-23. PubMed ID: 23957519
[TBL] [Abstract][Full Text] [Related]
14. Novel procedures for validating surrogate endpoints in clinical trials.
Cleophas TJ; Zwinderman AH; Chaib AH
Curr Clin Pharmacol; 2007 May; 2(2):123-8. PubMed ID: 18690859
[TBL] [Abstract][Full Text] [Related]
15. Nested combination tests with a time-to-event endpoint using a short-term endpoint for design adaptations.
Jörgens S; Wassmer G; König F; Posch M
Pharm Stat; 2019 May; 18(3):329-350. PubMed ID: 30652401
[TBL] [Abstract][Full Text] [Related]
16. Surrogate endpoints for overall survival in digestive oncology trials: which candidates? A questionnaires survey among clinicians and methodologists.
Methy N; Bedenne L; Bonnetain F
BMC Cancer; 2010 Jun; 10():277. PubMed ID: 20537166
[TBL] [Abstract][Full Text] [Related]
17. A Bayesian predictive sample size selection design for single-arm exploratory clinical trials.
Teramukai S; Daimon T; Zohar S
Stat Med; 2012 Dec; 31(30):4243-54. PubMed ID: 22807115
[TBL] [Abstract][Full Text] [Related]
18. A maximum entropy approach for the evaluation of surrogate endpoints based on causal inference.
Alonso A; Van der Elst W; Molenberghs G
Stat Med; 2018 Dec; 37(29):4525-4538. PubMed ID: 30141219
[TBL] [Abstract][Full Text] [Related]
19. Introduction to Bayesian methods III: use and interpretation of Bayesian tools in design and analysis.
Berry DA
Clin Trials; 2005; 2(4):295-300; discussion 301-4, 364-78. PubMed ID: 16281428
[TBL] [Abstract][Full Text] [Related]
20. Evaluating futility of a binary clinical endpoint using early read-outs.
Van Lancker K; Vandebosch A; Vansteelandt S; De Ridder F
Stat Med; 2019 Dec; 38(28):5361-5375. PubMed ID: 31631357
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
